Neuroblastoma Biology Study

Description

Medical scientists want to find better ways to treat neuroblastoma and to find ways to prevent the tumor from growing back. To do this, they need more information about the characteristics of neuroblastoma cells. Therefore, they want to study samples of neuroblastoma tissues and neuroblastoma and normal cells in the blood and bone marrow that may be related to the growth of neuroblastoma cells. Doctors and other medical scientists also want to find better ways to detect and measure neuroblastoma to improve the ability to follow the response of tumor cells to therapy.

Conditions

Neuroblastoma

Talk to us

Study Overview

On this page

Study Details

Study overview

Medical scientists want to find better ways to treat neuroblastoma and to find ways to prevent the tumor from growing back. To do this, they need more information about the characteristics of neuroblastoma cells. Therefore, they want to study samples of neuroblastoma tissues and neuroblastoma and normal cells in the blood and bone marrow that may be related to the growth of neuroblastoma cells. Doctors and other medical scientists also want to find better ways to detect and measure neuroblastoma to improve the ability to follow the response of tumor cells to therapy.

N2004-05: Neuroblastoma Biology Study

Neuroblastoma Biology Study

Condition
Neuroblastoma
Intervention / Treatment

-

Contacts and Locations

Los Angeles

Children's Hospital Los Angeles, Los Angeles, California, United States, 90027-0700

Palo Alto

Lucille Salter Packer Children's Hospital, Stanford University, Palo Alto, California, United States, 94305

San Francisco

UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States, 94115

Aurora

Children Hospital of Colorado, Aurora, Colorado, United States, 80045

Atlanta

AFLAC Cancer Center and Blood Disorders Service of Children's Healthcare of Atlanta - Egleston Campus, Atlanta, Georgia, United States, 30322

Chicago

University of Chicago, Comer Children's Hospital, Chicago, Illinois, United States, 60637

Boston

Children's Hospital Boston, Boston, Massachusetts, United States, 02115

Ann Arbor

C.S Mott Children's Hospital, Ann Arbor, Michigan, United States, 48109

Chapel Hill

University of North Carolina, Chapel Hill, North Carolina, United States, 27599

Cincinnati

Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States, 45229-3039

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Patients must be greater than or 31 days of age.
  • * Patients must have had a diagnosis of high risk neuroblastoma either by histological verification of neuroblastoma and/or demonstration of tumor cells in the bone marrow with increased urinary catecholamines.
  • * All patients with refractory or recurrent high risk neuroblastoma at NANT institutions are eligible regardless of disease status (including no measurable or evaluable tumor) as long as they undergo a disease evaluation and appropriate samples are submitted.
  • * Additionally, all patients with high risk neuroblastoma without relapse treated at a NANT institution are eligible if undergoing a disease evaluation, as long as Children's Oncology Group specimens are prioritized.
  • * There are no exclusion criteria on this study.

Ages Eligible for Study

31 Days to 99 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

New Approaches to Neuroblastoma Therapy Consortium,

Shahab Asgharzadeh, MD, STUDY_CHAIR, Children's Hospital Los Angeles

Study Record Dates

2099-12